Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B

Hepatology

Volumn 62, Issue 6, 2015, Pages 1697-1709

  Boni, Carolina ^a   Lampertico, Pietro ^b   Talamona, Lavinia ^a   Giuberti, Tiziana ^a   Invernizzi, Federica ^b   Barili, Valeria ^a   Fisicaro, Paola ^a   Rossi, Marzia ^a   Cavallo, Maria Cristina ^a   Vecchi, Andrea ^a   Pedrazzi, Giuseppe ^c   Alfieri, Arianna ^a   Colombo, Massimo ^b   Missale, Gabriele ^a   Ferrari, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE; NUCLEOTIDE;

BLOOD; FEMALE; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; MALE; NATURAL KILLER CELL; PHENOTYPE; PHYSIOLOGY; T LYMPHOCYTE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KILLER CELLS, NATURAL; MALE; NUCLEOSIDES; NUCLEOTIDES; PHENOTYPE; T-LYMPHOCYTES;

EID: 84955205698     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28155     Document Type: Article

References (21)

1. Lok AS, McMahon BJ. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
2. Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2015;64:526-528.
3. Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study. Gut 2015;64:667-672.
4. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-1764.
5. Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-973.
6. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-49.
7. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-868.
8. Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol 2012;3:351.
9. Maini MK, Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol 2013;4:57.
10. Schuch A, Hoh A, Thimme R. The role of natural killer cells and CD8+ T cells in hepatitis B virus infection. Front Immunol 2014;5:258.
11. Crouse J, Xu HC, Lang PA, Oxenius A. NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol 2015;36:49-58.
12. Klinke DJ, Brundage KM. Scalable analysis of flow cytometry data using R/Bioconductor. Cytometry 2009;75:699-706.
13. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 2010;6:e1001227.
14. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-1160.
15. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis 2014;209:1362-1373.
16. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011;54:209-218.
17. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-680.
18. Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013;210:99-114.
19. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A 2012;109:1210-1215.
20. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012;481:394-398.
21. Waggoner SN, Daniels KA, Welsh RM. Therapeutic depletion of natural killer cells controls persistent infection. J Virol 2014;88:1953-1960.